title: Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities.
abstract: S100A8 and S100A9 play important roles in immune and inflammatory disorders. The role of the two proteins in systemic sclerosis (SSc) remains unknown. Fifty-seven diffuse cutaneous SSc (dcSSc) patients, 31 limited cutaneous SSc (lcSSc) patients were recruited in the present study. The expression of S100A8 and S100A9 in plasma was measured using an enzyme-linked immunosorbent assay and the mRNA levels in peripheral blood were assessed using reverse transcriptase quantitative PCR. The expression and distribution of S100A8, S100A9, and receptor for advanced glycation end products (RAGE), in skin tissues was analyzed by immunohistochemistry. The plasma concentrations of S100A8 and S100A9 were significantly higher in dcSSc patients than in normal controls and lcSSc patients. Both S100A8 and S100A9 levels were significantly increased in dcSSc patients with lung or kidney involvement. Increased plasma levels of S100A8 and S100A9 in dcSSc patients were associated with several autoantibodies. Transcription levels of S100A8 and S100A9 in peripheral blood were found elevated in both dcSSc and lcSSc patients than normal controls. Immunohistochemistry demonstrated higher S100A8 and S100A9 expression in sclerotic skin than in normal skin. The number of S100A8, S100A9, or RAGE positive fibroblasts was also significantly increased. Highly elevated expression of both S100A8 and S100A9 was found in dcSSc patients. There was close correlation with disease severity and serological abnormalities, suggesting that the two proteins may play important roles in the development of systemic sclerosis.
authors.affiliation: Division of Rheumatology, Huashan Hospital, Fudan University, No. 12, Middle Wulumuqi Road, Shanghai, 200040, People's Republic of China.
authors.forename: Xue
authors.initials: X
authors.lastname: Xu
authors.forename: Wen-Yu
authors.initials: WY
authors.lastname: Wu
authors.forename: Wen-Zheng
authors.initials: WZ
authors.lastname: Tu
authors.forename: Hai-Yan
authors.initials: HY
authors.lastname: Chu
authors.forename: Xiao-Xia
authors.initials: XX
authors.lastname: Zhu
authors.forename: Min-Rui
authors.initials: MR
authors.lastname: Liang
authors.forename: Yu
authors.initials: Y
authors.lastname: Xue
authors.forename: Jiu-Cun
authors.initials: JC
authors.lastname: Wang
authors.forename: He-Jian
authors.initials: HJ
authors.lastname: Zou
mesh_terms: D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000276:immunology; D040501:Calgranulin A / Q000378:metabolism*; D040502:Calgranulin B / Q000378:metabolism*; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005347:Fibroblasts / Q000378:metabolism; D005786:Gene Expression Regulation; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D007668:Kidney / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D045743:Scleroderma, Diffuse / Q000276:immunology / Q000378:metabolism*; D012595:Scleroderma, Systemic / Q000276:immunology / Q000378:metabolism*; D012871:Skin Diseases / Q000276:immunology / Q000378:metabolism*
chemical_list: D001323:Autoantibodies; D040501:Calgranulin A; D040502:Calgranulin B; D017127:Glycation End Products, Advanced